Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
BioPharma Dive5h
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
STAT8h
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
STAT6h
Pharmalittle: We’re reading about a Merck deal, GSK cancer drug data, and more
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
Managed Healthcare Executive7h
Ebglyss Shows Improvement in Atopic Dermatitis Patients Who Stopped Dupixent
Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...
Fountain Life Adds Exclusive, Concierge Care Services to its APEX Premium Longevity Membership
Fountain Life, a longevity, preventative health, advanced diagnostics, and therapeutics company, today announced that it has ...
Nature21h
Drug screening articles from across Nature Portfolio
Drug screening is the process by which potential drugs are identified and optimized before selection of a candidate drug to progress to clinical trials. It can involve screening large libraries of ...